(via NewsDirect)
With three growing products addressing severe hypoglycemia, Cushing's Syndrome, and periodic peripheral paralysis, the company's core lies in commercial success.
Edick discussed a promising drug in development—levothyroxine—in a once-weekly subcutaneous injection format, targeting consistency and reduced side effects. Despite being in phase two, the drug could revolutionize current prescription norms.
Additionally, partnerships with industry giants like Regeneron and Amgen are underway, emphasizing Xeris' position as a formulation leader.
Financially robust, Xeris reported a record quarter and anticipates cash flow breakeven by the fourth quarter.
Edick affirmed the company's self-sustainability and projected ending 2024 with ample cash.
Despite market challenges, Xeris' growth and strategic focus signal confidence in its trajectory, positioning it as a force in biopharmaceutical innovation.
Contact Details
+1 347-449-0879
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source